Lifecore Biomedical, Inc. (LFCR) Key Metrics
LFCR valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $241.8M
- Enterprise value
- $307.8M
- P/E (TTM)
- — 10-yr median 27.2
- Forward P/E
- 8.7
- PEG ratio
- 2.66
- Price / sales
- 1.9 10-yr median 1.6
- Price / book
- 198.0 10-yr median 1.7
- EV / EBITDA
- 8.1 10-yr median 18.5
- Dividend yield
- —
- Beta
- 0.98
LFCR key metrics, FY2017–FY2026
Fiscal year ended May 31, 2026 · U.S. dollarsLFCR valuation Price multiples at each fiscal year-end price.
Price / sales−20.8%
1.4
FY2026 · hover or tap a bar for each year
FY2017FY2026
EV / EBITDA
37.9
FY2026 · hover or tap a bar for each year
FY2017FY2026
Price / free cash flow
30.1
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow yield+9.1 pts
3.3%
FY2026 · hover or tap a bar for each year
FY2017FY2026
LFCR returns How much profit the business earns on the capital it uses.
Return on invested capital+9.6 pts
−0.8%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets+2.6 pts
−13.1%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow margin+15.4 pts
4.8%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover+5.1%
0.55
FY2026 · hover or tap a bar for each year
FY2017FY2026
LFCR per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−6.4%
$3.46
FY2026 · hover or tap a bar for each year
FY2017FY2026
Earnings per share
−$0.82
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow per share
$0.17
FY2026 · hover or tap a bar for each year
FY2017FY2026
Book value per share
−$0.38
FY2026 · hover or tap a bar for each year
FY2017FY2026
Shares outstanding+7.3%
37.4M
FY2026 · hover or tap a bar for each year
FY2017FY2026
LFCR financial health Debt, liquidity and how easily interest is covered.
Net debt+$2.6M
$125.1M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Net debt / EBITDA
15.18
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio+23.0%
3.49
FY2026 · hover or tap a bar for each year
FY2017FY2026
Interest coverage
-0.6
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets+12.4%
0.61
FY2026 · hover or tap a bar for each year
FY2017FY2026
LFCR efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+3 days
109 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days of inventory−23 days
126 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days payables outstanding−22 days
29 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Cash conversion cycle+2 days
206 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Capex / revenue−5.5 pts
4.9%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Dividends + buybacks / FCF
31.2%
FY2026 · hover or tap a bar for each year
FY2017FY2026
LFCR valuation history
Fiscal year-endToday10-year median
LFCR returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LFCR debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LFCR cash returned to shareholders
DividendsBuybacksFree cash flow
LFCR price vs earnings per share
Share price at year-endEPS (right axis)
LFCR key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $187.6M | $235.7M | $214.1M | $241.3M | $280.4M | $350.6M | $311.2M | $283.8M | $393.6M | $387.1M |
| Enterprise value | $312.7M | $358.3M | $339.2M | $488.1M | $431.9M | $565.4M | $531.9M | $435.2M | $463.6M | $435.7M |
| P/E ratio | — | — | 17.8 | — | — | — | — | 133.7 | 15.9 | 36.6 |
| Price / sales | 1.4 | 1.8 | 1.7 | 2.2 | 1.5 | 3.5 | 1.9 | 0.5 | 0.8 | 0.7 |
| Price / book | — | 176.4 | 18.9 | 2.7 | 2.6 | 1.7 | 1.3 | 1.1 | 1.6 | 1.7 |
| Price / free cash flow | 30.1 | — | — | — | — | — | — | — | — | 57.5 |
| Price / operating cash flow | 14.9 | — | 833.0 | — | — | 21.3 | — | 17.7 | 19.9 | 13.2 |
| EV / sales | 2.4 | 2.8 | 2.6 | 4.4 | 2.3 | 5.6 | 3.3 | 0.8 | 0.9 | 0.8 |
| EV / EBITDA | 37.9 | — | 9.5 | 38.0 | — | — | — | 18.5 | 18.6 | 16.3 |
| EV / free cash flow | 50.2 | — | — | — | — | — | — | — | — | 64.7 |
| Earnings yield | −16.4% | −16.4% | 5.6% | −48.4% | −34.8% | −9.2% | −12.3% | 0.7% | 6.3% | 2.7% |
| Free cash flow yield | 3.3% | −5.8% | −8.5% | −21.8% | −18.7% | −2.5% | −14.1% | −10.1% | −3.5% | 1.7% |
| Dividend yield | — | — | 1.4% | 0.1% | — | — | 0.1% | 0.2% | — | — |
| Shareholder yield (dividends + buybacks) | 1.0% | — | 1.5% | 0.4% | — | 0.1% | 0.1% | 0.5% | 0.4% | 0.1% |
| Share price at fiscal year-end | $5.02 | $6.77 | $5.84 | $8.19 | $9.50 | $11.97 | $10.67 | $9.92 | $14.10 | $14.00 |
| Per share | ||||||||||
| Revenue per share | $3.46 | $3.70 | $3.50 | $3.78 | $6.30 | $3.44 | $5.49 | $19.49 | $18.78 | $19.25 |
| Earnings per share | −$0.82 | −$1.11 | $0.33 | −$3.96 | −$3.30 | −$1.10 | −$1.31 | $0.07 | $0.89 | $0.38 |
| Operating cash flow per share | $0.34 | −$0.01 | $0.01 | −$0.77 | −$0.83 | $0.56 | −$0.58 | $0.56 | $0.71 | $1.06 |
| Free cash flow per share | $0.17 | −$0.39 | −$0.49 | −$1.78 | −$1.78 | −$0.30 | −$1.50 | −$1.00 | −$0.49 | $0.24 |
| Cash per share | $0.47 | $0.24 | $0.23 | $0.03 | $0.06 | $0.04 | $0.01 | $0.04 | $0.10 | $0.20 |
| Book value per share | −$0.38 | $0.04 | $0.31 | $2.98 | $3.66 | $6.92 | $7.92 | $9.44 | $9.05 | $8.20 |
| Tangible book value per share | −$0.86 | −$0.48 | −$0.18 | $2.37 | $2.66 | $4.89 | $4.24 | $5.18 | $6.31 | $5.39 |
| Dividends per share | — | — | $0.08 | $0.01 | — | — | $0.01 | $0.02 | — | — |
| Capex per share | $0.17 | $0.39 | $0.50 | $1.02 | $0.95 | $0.86 | $0.92 | $1.56 | $1.20 | $0.82 |
| Debt per share | $3.82 | $3.76 | $3.64 | $8.41 | $5.19 | $7.37 | $7.58 | $5.33 | $2.61 | $1.95 |
| Shares outstanding | 37.4M | 34.8M | 36.7M | 29.5M | 29.5M | 29.3M | 29.2M | 28.6M | 27.9M | 27.7M |
| Change in shares outstanding | +7.3% | −5.0% | +24.4% | −0.2% | +0.7% | +0.5% | +1.9% | +2.5% | +1.0% | +1.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −612.1% | 24.2% | −119.2% | −62.7% | −14.9% | −15.2% | 0.8% | 10.4% | 4.8% |
| Return on invested capital (ROIC) | −0.8% | −10.5% | −3.7% | −3.1% | −0.8% | −1.6% | −4.7% | −1.3% | 4.0% | 4.1% |
| Return on assets (ROA) | −13.1% | −15.7% | 4.5% | −41.0% | −24.4% | −6.2% | −7.2% | 0.5% | 6.5% | 3.0% |
| Return on tangible assets | −14.4% | −17.5% | 5.1% | −45.5% | −36.7% | −7.3% | −8.8% | 0.5% | 7.6% | 3.8% |
| Free cash flow margin | 4.8% | −10.6% | −14.1% | −47.2% | −28.3% | −8.7% | −27.3% | −5.1% | −2.6% | 1.3% |
| Income quality (OCF / net income) | — | — | 0.02 | — | — | — | — | 7.55 | 0.80 | 2.77 |
| Financial health | ||||||||||
| Total debt | $142.6M | $130.8M | $133.6M | $247.8M | $153.2M | $215.9M | $221.1M | $152.5M | $72.9M | $54.0M |
| Cash & short-term investments | $17.5M | $8.3M | $8.5M | $991,000 | $1.6M | $1.2M | $360,000 | $1.1M | $2.9M | $5.4M |
| Net debt | $125.1M | $122.6M | $125.1M | $246.8M | $151.5M | $214.7M | $220.8M | $151.4M | $70.0M | $48.6M |
| Debt / equity | — | 97.92 | 11.81 | 2.82 | 1.42 | 1.06 | 0.96 | 0.56 | 0.29 | 0.24 |
| Debt / assets | 0.61 | 0.55 | 0.53 | 0.90 | 0.52 | 0.43 | 0.41 | 0.29 | 0.18 | 0.15 |
| Net debt / EBITDA | 15.18 | — | 3.52 | 19.21 | — | — | — | 6.45 | 2.80 | 1.82 |
| Current ratio | 3.49 | 2.84 | 2.08 | 0.66 | 1.56 | 1.46 | 0.96 | 0.97 | 1.10 | 1.58 |
| Quick ratio | 2.26 | 1.77 | 1.06 | 0.46 | 0.72 | 0.84 | 0.55 | 0.58 | 0.74 | 1.09 |
| Interest coverage | -0.6 | -0.8 | -0.5 | -0.8 | -0.2 | -1.0 | -5.6 | -1.5 | 6.1 | 8.5 |
| Working capital | $58.7M | $55.5M | $42.2M | −$59.9M | $44.5M | $46.4M | −$7.3M | −$4.0M | $8.7M | $29.8M |
| Invested capital | $110.9M | $123.9M | $136.4M | $334.6M | $259.5M | $417.5M | $451.8M | $421.6M | $322.6M | $275.2M |
| Tangible asset value | −$32.3M | −$16.7M | −$6.8M | $69.7M | $78.5M | $143.2M | $123.6M | $148.2M | $176.2M | $150.6M |
| Net current asset value | −$164.1M | −$152.3M | −$161.6M | −$70.2M | −$63.5M | −$151.8M | −$153.2M | −$115.9M | −$55.1M | −$48.6M |
| Graham number | — | — | $1.51 | — | — | — | — | $3.97 | $13.46 | $8.40 |
| Graham net-net per share | −$5.06 | −$5.19 | −$5.21 | −$4.72 | −$3.93 | −$8.07 | −$7.53 | −$5.89 | −$3.33 | −$2.80 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $3.1M | $274,000 | — | — | $212,000 | $700,000 | — | — |
| Share buybacks (net) | $1.9M | — | $152,000 | $789,000 | — | $405,000 | $212,000 | $700,000 | $1.5M | $434,000 |
| Dividend payout ratio | — | — | 25.6% | — | — | — | — | 33.0% | — | — |
| Dividends + buybacks / free cash flow | 31.2% | — | — | — | — | — | — | — | — | 6.4% |
| Capex / revenue | 4.9% | 10.4% | 14.3% | 26.9% | 15.1% | 25.0% | 16.7% | 8.0% | 6.4% | 4.2% |
| Capex / operating cash flow | 50.4% | — | 7,157.6% | — | — | 153.1% | — | 279.2% | 169.8% | 77.0% |
| Capex / depreciation | 0.67 | 1.67 | 2.31 | 1.66 | 1.57 | 1.27 | 1.42 | 2.94 | 2.71 | 2.12 |
| Stock-based compensation / revenue | 4.8% | 7.9% | 4.8% | 2.3% | 1.4% | 3.3% | 0.0% | 0.6% | 0.8% | 0.7% |
| R&D / revenue | 6.6% | 6.4% | 6.7% | 7.0% | 4.2% | 6.6% | 4.7% | 2.1% | 2.4% | 1.8% |
| SG&A / revenue | — | 34.2% | 33.5% | 38.3% | 24.8% | 64.7% | 45.0% | 11.5% | 9.9% | 10.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 109.2 | 106.0 | 98.8 | 141.9 | 88.0 | 212.8 | 166.2 | 40.4 | 34.7 | 31.6 |
| Days of inventory on hand | 126.1 | 148.9 | 160.5 | 259.9 | 175.1 | 381.2 | 182.1 | 32.9 | 23.4 | 20.7 |
| Days payables outstanding | 28.9 | 50.6 | 61.9 | 72.7 | 43.3 | 200.2 | 159.7 | 33.9 | 24.2 | 22.5 |
| Cash conversion cycle (days) | 206.4 | 204.3 | 197.5 | 329.1 | 219.9 | 393.9 | 188.6 | 39.4 | 33.9 | 29.8 |
| Receivables turnover | 3.34 | 3.44 | 3.69 | 2.57 | 4.15 | 1.72 | 2.20 | 9.03 | 10.51 | 11.53 |
| Payables turnover | 12.64 | 7.21 | 5.90 | 5.02 | 8.44 | 1.82 | 2.29 | 10.75 | 15.07 | 16.20 |
| Inventory turnover | 2.90 | 2.45 | 2.27 | 1.40 | 2.08 | 0.96 | 2.00 | 11.09 | 15.62 | 17.67 |
| Asset turnover | 0.55 | 0.52 | 0.49 | 0.39 | 0.47 | 0.19 | 0.30 | 1.21 | 1.37 | 1.52 |
| Average receivables | $38.7M | $37.4M | $34.7M | $43.2M | $44.8M | $58.8M | $72.9M | $61.7M | $49.9M | $46.2M |
| Average payables | $7.0M | $12.3M | $14.6M | $14.4M | $16.1M | $34.0M | $52.8M | $44.3M | $29.6M | $27.7M |
| Average inventory | $30.7M | $36.1M | $38.0M | $51.4M | $65.0M | $64.7M | $60.2M | $43.0M | $28.6M | $25.4M |
| Intangibles / total assets | 7.8% | 7.6% | 7.1% | 6.6% | 10.0% | 11.8% | 19.9% | 23.5% | 18.9% | 21.7% |
Computed from LFCR's annual financial statements (latest annual report filed March 16, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LFCR valuation and financial ratios
Lifecore Biomedical earned a return on invested capital of −0.8% in fiscal 2026. It ended the year with $142.6 million of debt and $17.5 million in cash and short-term investments, net debt of $125.1 million. It returned $1.9 million to shareholders: $0 in dividends and $1.9 million in share buybacks, 31% of free cash flow. The share count rose 35.1% from 27.7M to 37.4M over 9 years.
See the LFCR income statement, the LFCR chart for price history, or the LFCR stock overview for the latest quote and news.
LFCR key metrics FAQ
What is Lifecore Biomedical's EV/EBITDA?
Lifecore Biomedical's enterprise value was 37.9 times EBITDA at the end of fiscal 2026 (enterprise value $312.7 million, EBITDA $8.2 million); the current EV/EBITDA is 8.1.
What is Lifecore Biomedical's ROIC?
Lifecore Biomedical's return on invested capital was −0.8% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Lifecore Biomedical have?
Lifecore Biomedical had total debt of $142.6 million at the end of fiscal 2026 and $125.1 million of net debt (15.18 times EBITDA).
Does Lifecore Biomedical buy back its shares?
Yes. Lifecore Biomedical spent $1.9 million on net share repurchases in fiscal 2026 Shares outstanding changed +7.3% over the year, to 37.4M..
What is Lifecore Biomedical's free cash flow yield?
Lifecore Biomedical generated $6.2 million of free cash flow in fiscal 2026, a free cash flow yield of 3.3% on its market value at year-end ($187.6 million).
What is Lifecore Biomedical's current ratio?
Lifecore Biomedical's current ratio was 3.49 at the end of fiscal 2026: current assets were 3.49 times current liabilities.